CSIMarket Company Name, Ticker, Competitors, else..
 
Phio Pharmaceuticals Corp   (PHIO)
Other Ticker:  
 
 
Price: $2.6900 $0.01 0.373%
Day's High: $2.7 Week Perf: -4.27 %
Day's Low: $ 2.56 30 Day Perf: -18.24 %
Volume (M): 11 52 Wk High: $ 18.81
Volume (M$): $ 30 52 Wk Avg: $6.35
Open: $2.60 52 Wk Low: $2.40



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 1
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp is a biotechnology company that is focused on developing and commercializing RNA-based therapeutics for the treatment of various diseases. The company's proprietary RNAi technology platform allows for the silencing of disease-causing genes, potentially providing a novel approach to treating a wide range of conditions, including cancer, genetic disorders, and viral infections. Phio Pharmaceuticals is dedicated to advancing the field of RNA therapeutics and improving patients' lives through innovative treatment options.


   Company Address: 11 Apex Drive Marlborough 1752 MA
   Company Phone Number: 767-3861   Stock Exchange / Ticker: NASDAQ PHIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stocks on the Move

Phio Pharmaceuticals Sets Sights on Financial Turnaround with New CFO at the Helm

Published Mon, Aug 5 2024 4:14 PM UTC

In recent news, Phio Pharmaceuticals Corp (NASDAQ: PHIO), a clinical stage biotechnology company, has announced the appointment of a new Chief Financial Officer (CFO). This move comes as the company strives to improve its financial performance, which has been plagued by a cumulative net loss of $9 million during the 12 months ending in the first quarter of 2024. With a negat...
Stocks on the Move

The Under-Performance of Phio Pharmaceuticals Corp Shares A Review and Analysis

Published Fri, Jul 19 2024 7:30 PM UTC

Abstract:This article explores the recent under-performance of Phio Pharmaceuticals Corp shares and provides an analysis of the factors contributing to this trend. The study examines the impact of various events, including the exercise of warrants, termination of a share purchase agreement, and the company's financial performance. It also compares Phio Pharmaceuticals Corp's...
Stocks on the Move

Phio Pharmaceuticals Pioneering Advancements in Gene Silencing Technology

Published Tue, Jul 16 2024 7:23 AM UTC

Phio Pharmaceuticals Corp, a clinical stage biotechnology company focused on developing innovative siRNA gene silencing technology, has recently made several significant announcements that underline their commitment to advancing the field of pharmaceutical sciences.On July 12, 2024, Phio Pharmaceuticals announced the exercise of warrants, resulting in $3.1 million in gross p...
Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp Surprises Investors with Strong First Quarter Earnings Performance



During the earnings season for the first quarter of 2024, several companies, including Phio Pharmaceuticals Corp, operating in the Major Pharmaceutical Preparations industry, published their financial results. Phio Pharmaceuticals Corp, a company focused on developing technological solutions for cancer treatment, reported a significant decrease in operating losses compared to the same period last year. Additionally, the company made a groundbreaking discovery regarding the effectiveness of its lead product candidate, PH-762, in combating cancer cell growth.
Financial Results:
Phio Pharmaceuticals Corp published an operating loss of $-2.209 million for the most recent fiscal period. This represents an improvement compared to the operating loss of $-3.602 million in the first quarter of 2023. This reduction in losses is a positive sign for the company's financial situation and suggests that it is on track to becoming a standout leader in the industry. The decline in losses to $-2.154 million from $-3.602 million is an encouraging trend for Phio Pharmaceuticals Corp's future financial performance.
Clinical Study

Groundbreaking Breakthrough: Phios' PH-762 Intratumoral Injection Inhibits Tumor Growth and Stimulates Memory-Specific T cells.

Published Mon, Apr 22 2024 5:10 PM UTC

The recent breakthrough discovery of the effectiveness of Phios' PH-762 in combating cancer cell growth has risen as an emblem of hope for individuals diagnosed with cancer. The application of the intratumoral injection has shown a substantial reduction in tumor growth when tested in murine tumor models. The findings are influential, presenting a remarkable step forward in t...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com